- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Snapshot for Exelixis Inc (EXEL)
| Open: | 4.8000 | Day's Range: | 4.7100 - 4.8400 | Volume: | 1,047,176 |
|---|---|---|---|---|---|
| Previous Close: | 4.8200 | 52wk Range: | 4.1900 - 6.9500 | 1-Yr Rtn: | -7.63% |
Key Statistics for EXEL
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.9300 |
| Est. EPS (USD) (12/2013) | -1.2110 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 873.92 |
| Shares Outstanding (M) | 183.79 |
| 30 Day Average Volume | 1,378,866 |
| Price/Book (mrq) | 3.4039 |
| Price/Sale (ttm) | 20.7229 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for EXEL
Company Profile & Key Executives for EXEL
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.
| Stelios PapadopoulosNon-Exec Chairman/Co-Founder | Michael M MorrisseyPresident/CEO |
| Frank L KarbeExec VP/CFO | J Scott GarlandExec VP/Chief Commercial Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
EXEL News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page